UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
The new breast-cancer launch adds a growth opportunity and substantial obligations. Existing product sales and cash generation determine how much flexibility Rigel retains.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
VEPPANU became commercially available on August 13, 2026. The next financial report will begin to quantify its contribution alongside the established products. Rigel also expects preliminary R289 dose-expansion data by the end of 2026, following the planned second-half enrollment completion and dose selection. The commercial test is repeat demand and cash conversion; the clinical test is durable transfusion independence with manageable toxicity. The R289 timing is a company window, not a fixed regulatory decision date. Source Source
Rigel paid $70M upfront for VEPPANU in June 2026. Additional transition payments, development funding, royalties and supply commitments accompany the new product. June liquidity of $95.329M precedes the $32M July revolver repayment. Positive operating cash flow supports the business but does not guarantee that launch costs and commitments will be covered without further financing. Source Source
The favorable scenario requires Rigel to turn VEPPANU’s August 13, 2026 commercial launch into repeat prescriptions while maintaining the cash generation of its established products. The existing business provides a meaningful starting point: net product sales were $67.015 million in the quarter ended June 30, 2026, and operating cash flow was positive $33.378 million in the first half. A successful launch would add an oncology revenue stream without forcing a financing that transfers too much of the benefit to new shareholders. Approval and commercial availability are already facts; durable adoption and the eventual return on the license investment remain the tests. Source Source
The adverse scenario combines weaker core sales, slow VEPPANU adoption and expenditure that arrives before sufficient launch revenue. Rigel paid $70 million upfront in June 2026 for the license, while the agreement includes further transition payments, royalties and development commitments. A disappointing launch would therefore affect both future growth and the return on cash already committed. Source Source
The favorable scenario requires Rigel to turn VEPPANU’s August 13, 2026 commercial launch into repeat prescriptions while maintaining the cash generation of its established products. The existing business provides a meaningful starting point: net product sales were $67.015 million in the quarter ended June 30, 2026, and operating cash flow was positive $33.378 million in the first half. A successful launch would add an oncology revenue stream without forcing a financing that transfers too much of the benefit to new shareholders. Approval and commercial availability are already facts; durable adoption and the eventual return on the license investment remain the tests. Source Source
Rigel announces participation in September investor conferences. The notice is a corporate communication event, not a new clinical outcome or a product-sales update. Launch economics and the R289 timetable remain tied to the underlying company disclosures. Source
Rigel launches VEPPANU in the United States for the approved ESR1-mutated breast-cancer population after prior endocrine therapy. The announcement provides a $29,400 price per 30-day supply; discounts and other commercial terms determine the eventual net revenue. Source
Second-quarter product sales reach $67.015M, while first-half operating cash flow is positive $33.378M. The company reiterates $255–265M of 2026 core product sales excluding VEPPANU and the Form 10-Q reports the July revolver repayment, which leaves $8M outstanding. Form 10-Q. Source
The global VEPPANU license becomes effective June 11, with the $70M upfront payment completed. The subsequent August launch fulfills the earlier availability plan; the remaining question is the commercial and financial return on the acquired rights. Source
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
The favorable scenario requires Rigel to turn VEPPANU’s August 13, 2026 commercial launch into repeat prescriptions while maintaining the cash generation of its established products. The existing business provides a meaningful starting point: net product sales were $67.015 million in the quarter ended June 30, 2026, and operating cash flow was positive $33.378 million in the first half. A successful launch would add an oncology revenue stream without forcing a financing that transfers too much of the benefit to new shareholders. Approval and commercial availability are already facts; durable adoption and the eventual return on the license investment remain the tests. Source Source
The clinical evidence gives the launch a defined population. In the VERITAC-2 publication of May 31, 2025, median progression-free survival in the ESR1-mutated group was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. The favorable commercial case requires this benefit to translate into prescribing, access and continued treatment in the approved population. It does not require assuming that every patient with hormone-sensitive breast cancer qualifies. Source Source
The central scenario is an uneven launch supported by the older products. Rigel’s August 4, 2026 guidance called for $255–265 million of full-year net product sales excluding VEPPANU, plus approximately $30 million of collaboration revenue. That leaves the launch as a separate contributor whose initial sales can be modest without automatically invalidating the existing commercial plan. TAVALISSE remains especially important because it generated $47.4 million of the second quarter’s product sales. Source
Under this scenario, the next reports show a mixture of launch spending, inventory investment, royalties and early revenue. Cash generation can fluctuate as customers pay and supply is purchased. The window through year-end 2026 for preliminary R289 expansion data provides a second source of possible news, but that program remains early clinical development. The company can make progress without every quarter delivering both a strong launch and a decisive pipeline result. Source Source
The adverse scenario combines weaker core sales, slow VEPPANU adoption and expenditure that arrives before sufficient launch revenue. Rigel paid $70 million upfront in June 2026 for the license, while the agreement includes further transition payments, royalties and development commitments. A disappointing launch would therefore affect both future growth and the return on cash already committed. Source Source
The balance sheet would not make that risk disappear. Rigel reported $95.329 million of cash, equivalents and short-term investments at June 30, 2026, before a $32 million revolver repayment in July. The company also has equity issuance capacity and substantial outstanding employee awards. If commercial execution deteriorates, additional financing could preserve operations while reducing the benefit per existing share. An unfavorable R289 update could compound the pressure, but the established products and their cash contribution remain the first place to measure deterioration. Source
The constructive reading depends on the established products continuing to fund operations while VEPPANU becomes a commercially useful addition. These developments would weaken that reading.
These are observations that would weaken the interpretation, not forecasts of inevitable events.
Rigel is a commercial biotechnology company with exposure to hematology and oncology. Its existing U.S. portfolio includes TAVALISSE for chronic immune thrombocytopenia in adults with an insufficient response to prior treatment, REZLIDHIA for specified IDH1-mutated relapsed or refractory acute myeloid leukemia, and GAVRETO for its approved RET-altered cancer indications. VEPPANU joined the commercially available portfolio on August 13, 2026. These are separate markets with different prescribers, competitive pressures and payment arrangements; treating them as one interchangeable sales stream hides where performance is coming from. Source Source
TAVALISSE supplied $47.4 million of second-quarter 2026 net product sales, compared with $40.1 million a year earlier. REZLIDHIA contributed $8.9 million versus $7.0 million, while GAVRETO contributed $10.7 million versus $11.8 million. The August 4 release described year-over-year growth of 18% and 27% for TAVALISSE and REZLIDHIA, respectively, alongside a 10% decline for GAVRETO. The overall portfolio grew, but participation was uneven. Source
The first-half comparison tells a similar story. TAVALISSE sales reached $84.7 million, REZLIDHIA $17.0 million and GAVRETO $20.3 million for the six months ended June 30, 2026. The filing attributes TAVALISSE’s growth to volume, price per bottle and favorable revenue reserves; REZLIDHIA benefited from volume and price, partially offset by higher reserves. GAVRETO faced lower volume and higher reserves, partially offset by price. Those details matter because stronger reported revenue can reflect more than new patients. Source
The useful comparison in the next report is therefore product by product. Continued TAVALISSE volume growth would make the funding of a new launch more credible. A quarter supported mainly by price or reserve movements would deserve a more cautious interpretation. Stabilization at GAVRETO would help diversify the contribution; continued contraction would make VEPPANU’s incremental growth more important.
Rigel also receives collaboration revenue and royalties, including from partners developing or selling products outside its direct commercial footprint. Those receipts have economic value, but milestone revenue can be irregular. An overseas filing milestone and a recurring prescription sale do not offer the same visibility. The core question is whether the products under Rigel’s direct commercial responsibility can support an expanding cost base even when a partner milestone does not recur. Source
The August 13, 2026 launch announcement made VEPPANU available by prescription in the United States for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorized test, after disease progression following at least one line of endocrine therapy. That label defines the immediate commercial opportunity. Broader breast-cancer prevalence is not the addressable population for this particular approval. Source
Vepdegestrant is a protein degrader that recruits the cell’s own machinery to remove the estrogen receptor. The commercial relevance of the mechanism is the possibility of activity in endocrine-resistant disease; novelty by itself does not establish superior reimbursement, prescribing share or patient persistence. Source
Rigel announced a U.S. price of $29,400 per 30-day supply at launch on August 13, 2026. This is a stated product price, not the net revenue that Rigel will collect for every treated patient. Discounts, rebates, assistance arrangements, distribution economics and treatment duration affect the realized amount. Multiplying that price by a broad patient estimate would overstate the precision of a sales forecast. Source
The company is using specialty distribution, specialty pharmacies and its RIGEL ONECARE support program. For the equity story, the important signs are whether eligible patients can obtain the medicine, whether physicians prescribe it repeatedly, and whether access produces revenue that turns into collected cash. Inventory placed in a distribution channel can help a launch begin, but repeat demand is the stronger evidence of a sustainable franchise. Source Source
The first reporting periods will also contain a short period of availability rather than a mature run rate. A strong opening shipment and a slow opening shipment can each be misleading if read without subsequent prescriptions, returns, reserves and cash collection. The most useful management explanation would connect reported revenue with underlying demand and the expense needed to generate it.
Rigel’s August 4, 2026 revenue guidance expressly excluded VEPPANU from the $255–265 million net product sales range. That treatment is not a forecast of no launch sales. It means the published core range and the new product’s contribution need to be evaluated separately. The launch can create upside, but its contribution should enter a valuation only with explicit assumptions about adoption, net pricing, duration and costs. Source
The pivotal VERITAC-2 paper published May 31, 2025 enrolled 624 patients overall. Among the 270 patients with ESR1 mutations, median progression-free survival was 5.0 months for vepdegestrant and 2.1 months for fulvestrant, with a hazard ratio of 0.58, a 95% confidence interval of 0.43–0.78 and p<0.001. That is the important efficacy result supporting the biomarker-defined commercial thesis. The hazard ratio describes a relative difference in progression or death risk over follow-up; it does not mean every patient’s disease is controlled for a fixed additional period. Source
The same publication did not establish a statistically significant progression-free survival benefit in the entire trial population: medians were 3.8 and 3.6 months, the hazard ratio was 0.83 with a 95% confidence interval of 0.69–1.01, and p=0.07. The distinction matters commercially because the positive selected-population result should not be generalized to all ER-positive, HER2-negative disease. Nor should progression-free survival be described as proof of an overall survival advantage. Source
Safety also belongs in the commercial assessment. In VERITAC-2, grade 3 or higher adverse events occurred in 23.4% of vepdegestrant patients and 17.6% of fulvestrant patients; discontinuation because of adverse events occurred in 2.9% and 0.7%, respectively, as reported in the May 2025 publication. Low discontinuation does not mean that serious toxicity is absent. Source
The August 13, 2026 prescribing announcement highlights QTc prolongation, embryo-fetal toxicity and clinically relevant drug interactions. Those warnings can affect monitoring, choice of therapy and the practicality of treatment in a patient already taking other medicines. They do not establish that the medicine will fail commercially; they are part of the real-world tradeoff that headline efficacy percentages leave out. Source
For the stock, the question has moved beyond whether the pivotal result exists. It is whether the approved benefit, safety profile and oral administration support a meaningful position in the treatment sequence. Competitive therapies, patient testing and reimbursement can each influence that outcome. The clinical result gives a basis for the launch, while the commercial reports will show how much economic value that basis creates for Rigel.
At June 30, 2026, Rigel held $60.816 million of cash and equivalents and $34.513 million of short-term investments, a calculated total of $95.329 million. The corresponding total at December 31, 2025 was $154.955 million. The cash-flow statement includes an additional $0.057 million of restricted cash in its cash reconciliation; that amount is not included in the unrestricted liquidity total. These are balance-sheet dates, not an October bank balance. Source
Operating activities generated $33.378 million during the first six months of 2026, compared with $29.644 million in the prior-year period. Dividing the current figure by six gives a calculated historical monthly operating inflow of approximately $5.563 million. Calling that a monthly burn would reverse the sign. Dividing cash by that positive inflow to announce a fixed runway would also be inappropriate. Source
The cash balance nevertheless declined because operating cash generation is only one part of capital allocation. The first-half cash-flow statement reports $70.347 million for the acquisition of an intangible asset and $55.250 million of term-loan principal and related fee payments, alongside $40 million of new revolver proceeds. The business was generating operating cash while simultaneously investing in a license and restructuring its financing. Source
This distinction is central to the next reports. Positive operations can fund a portion of growth, but a major acquisition, supply commitment or debt payment can still reduce available liquidity. Conversely, a decline in cash after a disclosed strategic payment is not automatically evidence that the existing drugs have become cash-burning products. The explanation has to connect sales, expenses, working capital, investment and financing.
Working capital deserves particular attention during the launch. Accounts receivable were $56.041 million at June 30, 2026, versus $51.763 million at the preceding year-end. Collection timing affects cash even when revenue recognition is unchanged. Inventories, including longer-term holdings, and prepaid supply also consume resources before the related product is sold. Growing receivables can be normal during expansion, but persistent growth faster than sales would weaken the quality of reported progress. Source
The June balance sheet also contained a $238.068 million deferred tax asset. It represents expected future tax benefits under the accounting assumptions, not cash available to pay a license installment, meet a loan covenant or purchase inventory. Treating total book equity or that tax asset as freely spendable financial capacity would exaggerate the immediate cushion. Source
The MidCap revolver replaced the older term loan in May 2026. The facility has a $40 million maximum, with a potential increase to $60 million subject to conditions, and final contractual repayment no later than May 31, 2031. Interest is one-month SOFR, subject to a 2% floor, plus 4%; the weighted average rate on June 30, 2026 was 7.6%. Availability depends primarily on eligible receivables and inventory, so the headline facility size is not unconditional cash. Source
Rigel had $40 million of principal outstanding at June 30, 2026 and repaid $32 million in July, leaving $8 million outstanding after that repayment. The June balance sheet carries the debt as current under the facility’s structure and circumstances. That classification does not mean the final contractual maturity was suddenly moved to 2026. The July reduction is relevant, but it postdates the June cash figure; the two do not come from a single later balance sheet. Source
The facility is secured by substantially all assets, including intellectual property. It includes liquidity and trailing product revenue covenants, with the revenue test applying when liquidity falls below specified thresholds. The company reported compliance at June 30, 2026. These conditions can influence management’s choices if launch spending accelerates or commercial cash collection weakens. Borrowing capacity is useful flexibility, not a substitute for operating performance. Source
VEPPANU adds a separate set of obligations. The agreement effective June 11, 2026 requires a license fee of up to $85 million, including the $70 million already paid and up to $15 million upon completion of transition activities. Potential regulatory milestones total up to $60 million and commercial milestones up to $260 million. Annual net sales also carry royalties ranging from the mid-teens to the mid-twenties, subject to contractual adjustments. These contingent amounts are not all current debt, but successful sales do not accrue entirely to Rigel. Source Source
The license also includes reimbursement of specified ongoing development costs up to $40 million, with funding caps through 2029. A July 2026 Pfizer supply agreement added approximately $26.8 million of estimated minimum purchase obligations through 2030, including approximately $4.6 million expected in the remainder of 2026. The commercial opportunity therefore comes with both variable royalties and commitments that can require cash before a mature sales base exists. Source
Rigel’s August 4, 2026 outlook called for total revenue of $285–295 million, composed of $255–265 million of net product sales excluding VEPPANU and approximately $30 million of collaboration revenue. First-half product sales were $121.938 million. Subtracting that reported figure from the full-year core product range implies a calculated second-half requirement of approximately $133.062–143.062 million, excluding VEPPANU. This is an arithmetic implication of management’s range, not a separate company forecast. Source Source
The comparison gives the next results a concrete test: can the established portfolio deliver the required second-half contribution while commercial resources also support the new launch? Strong VEPPANU revenue would be welcome, but it should not conceal a shortfall in the original product assumptions. Likewise, a lumpy collaboration payment can lift total revenue without demonstrating stronger recurring prescription demand.
Second-quarter 2026 total revenue was $78.703 million versus $101.685 million a year earlier, despite the increase in product sales to $67.015 million from $58.948 million. The explanation lies mainly in collaboration revenue: the prior-year quarter included a roughly $40 million noncash release of a Lilly cost-sharing liability. Revenue declined against an unusual comparison, while the commercial product business grew. Source
The Lilly agreement was terminated effective June 15, 2026, with the licensed rights returning to Rigel under its terms. The former collaboration’s prospective milestone package should therefore not remain in a current valuation as though the agreement were still active. Any future value from the returned rights would need a new development or partnering path. Source
Reported second-quarter 2026 net income was $17.290 million, down from $59.613 million in the comparable quarter. Research and development expense increased to $13.961 million from $6.821 million, and selling, general and administrative expense increased to $32.642 million from $29.257 million. VEPPANU-related work and the wider development program add costs as well as opportunity. The next earnings assessment should separate operating growth, launch spending, noncash compensation, royalties and tax accounting before drawing conclusions from a single profit percentage. Source
Rigel reported 18,653,941 common shares outstanding at June 30, 2026 and 18,679,864 at July 30 on the quarterly report’s cover. The latter is a point-in-time count, while the second quarter’s diluted earnings denominator was a weighted average of approximately 19.570 million shares. These measures answer different questions and should not be swapped when discussing ownership or earnings per share. Source
At June 30, 2026, 3,351,295 options and 972,970 restricted stock units were outstanding. The company also had 1,181,836 shares available for future grants under its equity incentive plans and 396,349 available under its employee stock purchase plan. Outstanding awards and ungranted capacity are not all shares already issued, but they show why a stable headline share count does not eliminate future dilution. Source
The April 2026 proxy states that the 2018 incentive plan has no annual evergreen provision; shareholders approved a further 500,000-share increase in May, as subsequently reported in the June quarterly filing. The annual report recorded 400 million authorized common shares at December 31, 2025. Legal authorization, approved plan reserves and actual issuance remain distinct. The very large authorized ceiling is not an immediate forecast of shares entering the market. Source Source Source
Financing flexibility includes a $100 million ATM within a $250 million shelf, according to the June 2026 filing. Rigel reported no sales under that ATM through June 30. This is a dated statement about the reported period, not a guarantee against later issuance. A profitable company can still use equity for an acquisition, launch or balance-sheet objective; future proceeds would need to be weighed against the additional denominator. Source
The September 3, 2026 insider filings should also be read by transaction type. CEO Raul Rodriguez reported a September 1 disposition of 2,424 shares coded F, which denotes shares delivered or withheld for an exercise price or tax obligation, rather than an ordinary open-market sale. The same filing notes the return of 3,807 shares previously reported under the employee purchase plan. CFO Dean Schorno reported a September 1 F-coded disposition and September 2 option exercises totaling 4,600 shares, coded M. These are not evidence of a discretionary market purchase or sale simply because an aggregator displays them in a transaction feed. Source Source
The Nasdaq reference close was $46.97 on October 1, 2026, in the Finviz daily data. Market data as of October 2 showed an approximately 18.06 million-share float, short interest equal to 17.67% of float and a short ratio of 10.37. The settlement date of the underlying short-interest figure is not stated. The data are as of October 2, and the ratio is a statistical measure rather than a promise that short positions can be covered in that number of sessions. Source Source
The same October 2 snapshot reported institutional ownership of 88.59% and insider ownership of 3.32%. Third-party ownership categories depend on their filing and aggregation conventions, so they are not a perfectly synchronized ownership register. The company’s April 2026 proxy, using a January 31 share-count basis, listed BlackRock with 1,381,983 shares and State Street with 1,091,223. Those named positions are historical disclosures; they are not October holdings inferred from the current third-party percentage. Source Source
Short exposure can amplify reactions to a new sales trajectory or pipeline data, particularly when normal daily turnover is limited. It does not make a squeeze inevitable and cannot replace an operating thesis. A short position may reflect valuation, launch skepticism, hedging or other portfolio decisions that are not visible in an aggregate percentage.
The relevant distinction is between a trading catalyst and a sustained business change. A sharp response to an update can occur before the market has enough evidence to estimate recurring sales. The stronger test is whether subsequent prescriptions, product revenue and cash conversion validate the change in expectations. Market data describe the trading conditions around that test; they do not justify a directional price target.
Rigel’s August 4, 2026 update expected completion of the R289 dose-expansion enrollment and selection of a recommended Phase 2 dose in the second half of 2026, with preliminary expansion data by year-end. These are company timing windows. They are not an FDA decision date, and completion of enrollment is a different event from having sufficiently mature results to assess benefit. Source Source
The earlier data presented on December 7, 2025, using an October 28 cutoff, included 33 enrolled patients with lower-risk MDS. Among 18 evaluable transfusion-dependent patients at the specified higher dose levels and with at least 16 weeks of follow-up, six achieved red-cell transfusion independence lasting more than eight weeks, a reported 33%. Four exceeded 16 weeks and three exceeded 24 weeks. This was an early clinical signal in a selected evaluable subset, not a randomized estimate of superiority over standard treatment. Source
The same presentation reported a dose-limiting liver enzyme toxicity in one patient and grade 3 or 4 events including anemia, decreased neutrophils and pneumonia. The next data will only be meaningful when the response denominator, duration, follow-up and tolerability are considered together. A higher percentage in a small group is less persuasive if follow-up is short or treatment cannot be maintained. Source
The commercial checkpoint is equally concrete. The next financial report should reveal the initial VEPPANU contribution, the performance of each established product, collections and launch-related costs. At the same time, updated borrowing and cash figures will show the effect of the July repayment and the new supply obligations. These reporting items should be evaluated together rather than using one favorable launch headline to infer a fully funded growth cycle. Source Source
The clearest red flags would be deterioration in TAVALISSE’s underlying demand, persistent weakness at GAVRETO, rising launch costs without repeat demand, or cash collection that trails the revenue narrative. For R289, a delayed update, weaker durability or a more restrictive safety profile would reduce the contribution that can reasonably be assigned to the pipeline. These are conditions to monitor, not claims that they have occurred.
Rigel’s practical investment question is whether an operating business that generated cash in the first half can turn a newly licensed cancer treatment into profitable incremental growth. The established drugs provide a commercial base; VEPPANU supplies a new opportunity and new obligations; R289 offers a separate, still early clinical catalyst. The case becomes stronger when all three are assessed through dated sales, collected cash and evidence that survives follow-up, rather than through an assumed launch curve or a short-interest narrative. Source Source Source
VEPPANU is an approved product and became commercially available in the United States on August 13, 2026 for its specified ESR1-mutated breast-cancer indication. The current question is adoption and economic contribution, not whether the initial launch will occur. Source
Operating activities generated $33.378M in the six months ended June 30, 2026, a calculated historical average inflow of about $5.563M a month. That is positive operating cash generation, not burn. License investment and financing payments must be evaluated separately, and this figure does not establish a fixed runway. Source
The August 4, 2026 outlook specified $255–265M of product sales excluding VEPPANU, plus approximately $30M of collaboration revenue. Exclusion from that range is not a forecast of zero launch sales. Source
The June 30, 2026 revolver principal was $40M. A $32M repayment in July left $8M outstanding afterward. That later debt figure and June cash together do not represent an October balance sheet. Source
The August 4, 2026 update expected preliminary dose-expansion data by year-end 2026, with enrollment completion and recommended Phase 2 dose selection in the second half. This is a company timing window, subject to clinical execution and data maturity. Source
The September 3, 2026 filings discussed here report F-coded withholding or delivery transactions and, for CFO Dean Schorno, M-coded option exercises. Those codes do not describe ordinary discretionary open-market sales or purchases. Each transaction must be classified from its filing. Source Source
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $RIGL or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
